We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
New data from a Phase III trial of AstraZeneca and MSD’s Lynparza (olaparib) has shown that 22% of patients receiving the monotherapy remained free of disease progression after two years vs. 10% on placebo, making the drug the first PARP inhibitor to demo